Atlas Trials

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

Clinical trial NCT02951052 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02951052
Sponsor
ViiV Healthcare
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Infection, Human Immunodeficiency VirusHIV Infections
Start date
2016-10-28
Primary completion
2018-05-29
Enrollment
618

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.